CytoMed Therapeutics Limited Stock Analysis & AI Score
CytoMed Therapeutics Limited (GDTC) has an ST Score of 23.0 (D+), driven by its Momentum (C) and held back by its Growth (F). Analysts rate it Buy.
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
CytoMed Therapeutics Limited (GDTC) has an ST Score of 23.0 (D+), driven by its Momentum (C) and held back by its Growth (F). Analysts rate it Buy.
- Strongest
- MomentumC
- Weakest
- GrowthF
All factor grades
- MomentumC
- ValuationC-
- ProfitabilityC-
- Financial StrengthD+
- GrowthF
- Piotroski2/9
Contact
GDTC stock: frequently asked questions
What is GDTC's ST Score?
CytoMed Therapeutics Limited (GDTC) has an ST Score of 23.0 (D+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is GDTC a buy, hold, or sell?
Analysts rate GDTC a Buy. Our ST Score grades it D+ (23.0/100). The ST Score is a data-driven signal, not a recommendation.
What are GDTC's factor grades?
Valuation C-, Profitability C-, Financial Strength D+, Momentum C, Growth F.
What is GDTC's valuation grade?
CytoMed Therapeutics Limited (GDTC) earns a valuation grade of C-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is GDTC's growth grade?
CytoMed Therapeutics Limited (GDTC) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is GDTC's profitability grade?
CytoMed Therapeutics Limited (GDTC) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is GDTC's financial strength grade?
CytoMed Therapeutics Limited (GDTC) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is GDTC's Piotroski score?
CytoMed Therapeutics Limited (GDTC) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.